Skip to main content
Premium Trial:

Request an Annual Quote

Seventh Sense Biosystems, Miraca Sign Distribution, Investment Deal

NEW YORK — Seventh Sense Biosystems announced today that it has signed a distribution and equity investment deal with Japanese commercial clinical lab Miraca.

Medford, Massachusetts-based Seventh Sense markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm. It was cleared by the US Food and Drug Administration in 2017 and was CE marked last year.

Under the terms of the deal, Miraca will distribute Tap products in Japan and has taken an undisclosed stake in Seventh Sense. Additional terms were not disclosed.

In late 2017, antisense drug developer Ionis Pharmaceuticals made a $2 million investment in Seventh Sense as part of a Series C financing round.